Study led by UC Irvine shows drug combo better for certain metastatic breast cancer:
NCI Cancer Center News
Post-menopausal women with a certain type of metastatic breast cancer may have a new treatment option that could lengthen their lives, according a study led by UC Irvine… The findings were presented today at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium. The combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to those who underwent standard treatment with anastrozole alone.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.